Kevin Young
2016
In 2016, Kevin Young earned a total compensation of $5.6M as Chief Operating Officer at Gilead Sciences.
Compensation breakdown
| Non-Equity Incentive Plan | $954,293 |
|---|---|
| Option Awards | $1,910,839 |
| Salary | $787,645 |
| Stock Awards | $1,911,323 |
| Other | $75,574 |
| Total | $5,639,674 |
Young received $1.9M in stock awards, accounting for 34% of the total pay in 2016.
Young also received $954.3K in non-equity incentive plan, $1.9M in option awards, $787.6K in salary and $75.6K in other compensation.
Rankings
In 2016, Kevin Young's compensation ranked 1,342nd out of 14,075 executives tracked by ExecPay. In other words, Young earned more than 90.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,342 out of 14,075 | 91st |
Division Manufacturing | 453 out of 5,488 | 92nd |
Major group Chemicals And Allied Products | 123 out of 1,900 | 94th |
Industry group Drugs | 83 out of 1,543 | 95th |
Industry Biological Products, Except Diagnostic Substances | 15 out of 287 | 95th |
Source: SEC filing on March 26, 2018.
Young's colleagues
We found four more compensation records of executives who worked with Kevin Young at Gilead Sciences in 2016.